Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium Maltolate in Pediatric High-Grade Glioma and ATRT
NCT07331064Phase 1Not yet recruiting
- Sponsor
- Sarah Rumler
- Start
- May 2026
- Primary completion
- Nov 2030
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of gallium maltolate in glioma, Atypical teratoid rhabdoid tumor (ATRT), diffuse midline glioma (DMG) and 1 more, sponsored by Sarah Rumler. Primary endpoints: Gallium Maltolate Tolerance, Recommended Phase 2 Dose and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
gallium maltolate
03
Conditions
gliomaAtypical teratoid rhabdoid tumor (ATRT)diffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT07331064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331064.